Prevention of Diabetes With Pioglitazone in ACT NOW
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 42 of the 42 references it cites were found in a registry or an index.
Abstract
We examined the metabolic characteristics that attend the development of type 2 diabetes (T2DM) in 441 impaired glucose tolerance (IGT) subjects who participated in the ACT NOW Study and had complete end-of-study metabolic measurements. Subjects were randomized to receive pioglitazone (PGZ; 45 mg/day) or placebo and were observed for a median of 2.4 years. Indices of insulin sensitivity (Matsuda index [MI]), insulin secretion (IS)/insulin resistance (IR; ΔI0–120/ΔG0–120, ΔIS rate [ISR]0–120/ΔG0–120), and β-cell function (ΔI/ΔG × MI and ΔISR/ΔG × MI) were calculated from plasma glucose, insulin, and C-peptide concentrations during oral glucose tolerance tests at baseline and study end. Diabetes developed in 45 placebo-treated vs. 15 PGZ-treated subjects (odds ratio [OR] 0.28 [95% CI 0.15–0.49]; P < 0.0001); 48% of PGZ-treated subjects reverted to normal glucose tolerance (NGT) versus 28% of placebo-treated subjects (P < 0.005). Higher final glucose tolerance status (NGT > IGT > T2DM) was associated with improvements in insulin sensitivity (OR 0.61 [95% CI 0.54–0.80]), IS (OR 0.61 [95% CI 0.50–0.75]), and β-cell function (ln IS/IR index and ln ISR/IR index) (OR 0.26 [95% CI 0.19–0.37]; all P < 0.0001). Of the factors measured, improved β-cell function was most closely associated with final glucose tolerance status.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, changes such as regression to IGT, maintenance of NGT, or progression to diabetes were proportional to insulin secretion response ( 67 ).”
From β-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment (2014) · cites this paper as [67]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matsuda, M., & DeFronzo, R. A. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1462 · Cited by 5,621 · cited 1×
“from PG and insulin levels obtained during the OGTT (23).”
BackgroundSelf-citationPrevalence of Obesity and Trends in the Distribution of Body Mass Index Among US Adults, 1999-2010
Flegal, K. M., Carroll, M. D., Kit, B. K., & Ogden, C. L. (2012) · JAMA · doi:10.1001/jama.2012.39 · Cited by 5,385 · cited 1×
“The prevalence of type 2 diabetes mellitus (T2DM) has risen to epidemic proportions in the United States and worldwide (1), and is being driven by the epidemic of obesity (2).”
BackgroundDormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129 · cited 1×
“In contrast, PGZ does not increase the number of cardiovascular events (31,32).”
BackgroundThe Triumvirate: β-Cell, Muscle, Liver: A Collusion Responsible for NIDDM
DeFronzo, R. A. (1988) · Diabetes · doi:10.2337/diab.37.6.667 · Cited by 2,456 · cited 2×
“Glucotoxicity has been implicated in progressive b-cell failure as individuals move from NGT to IGT to T2DM (8).”
BackgroundSelf-citationWeyer, C., Bogardus, C., Mott, D. M., & Pratley, R. E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7231 · Cited by 1,940 · cited 2×
“Alternatively, since PPAR-g is present in muscle/liver and b-cells (10,13), simultaneous PPAR-g activation in these tissues could explain the strong association between improved insulin sensitivity and enhanced b-cell function.”
BackgroundResultYki-Järvinen, H. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041001 · Cited by 1,830
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827 · cited 2×
“PGZ reduces plasma free fatty acid (FFA) levels, mobilizes fat out of muscle (21) and liver (22), and redistributes fat from visceral to subcutaneous depots (12,16).”
BackgroundSelf-citationPPAR-gamma: adipogenic regulator and thiazolidinedione receptor.
Spiegelman, B. M. (1998) · Diabetes · doi:10.2337/diabetes.47.4.507 · Cited by 1,730
Buchanan, T. A., Xiang, A. H., Peters, R. K., Kjos, S. L., Marroquin, A., Goico, J., Ochoa, C., Tan, S., Berkowitz, K., Hodis, H. N., et al. (2002) · Diabetes · doi:10.2337/diabetes.51.9.2796 · Cited by 1,339
Self-citation
Cited by
DeFronzo, R. A., Ferrannini, E., Groop, L., Henry, R. R., Herman, W. H., Holst, J. J., Hu, F. B., Kahn, C. R., Raz, I., Shulman, G. I., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.19 · Cited by 2,611
Self-citationAhmad, E., Lim, S., Lamptey, R., Webb, D. R., & Davies, M. J. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01655-5 · Cited by 1,120
Evidence of β-Cell Dedifferentiation in Human Type 2 Diabetes
Cinti, F., Bouchi, R., Kim-Muller, J. Y., Ohmura, Y., Sandoval, P. R., Masini, M., Marselli, L., Suleiman, M., Ratner, L. E., Marchetti, P., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2860 · Cited by 550
β-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment
Halban, P. A., Polonsky, K. S., Bowden, D. W., Hawkins, M. A., Ling, C., Mather, K. J., Powers, A. C., Rhodes, C. J., Sussel, L., & Weir, G. C. (2014) · Diabetes Care · doi:10.2337/dc14-0396 · Cited by 460
Tan, S. Y., Mei Wong, J. L., Sim, Y. J., Wong, S. S., Mohamed Elhassan, S. A., Tan, S. H., Ling Lim, G. P., Rong Tay, N. W., Annan, N. C., Bhattamisra, S. K., et al. (2019) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2018.10.008 · Cited by 445
Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes
Ferrannini, E., & DeFronzo, R. A. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv239 · Cited by 258
Self-citationβ-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment
Halban, P. A., Polonsky, K. S., Bowden, D. W., Hawkins, M. A., Ling, C., Mather, K. J., Powers, A. C., Rhodes, C. J., Sussel, L., & Weir, G. C. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1425 · Cited by 222
Pioglitazone: the forgotten, cost-effective cardioprotective drug for type 2 diabetes
DeFronzo, R. A., Inzucchi, S., Abdul-Ghani, M., & Nissen, S. E. (2019) · Diabetes and Vascular Disease Research · doi:10.1177/1479164118825376 · Cited by 223
Self-citationBril, F., Kalavalapalli, S., Clark, V. C., Lomonaco, R., Soldevila-Pico, C., Liu, I.-C., Orsak, B., Tio, F., & Cusi, K. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.12.001 · Cited by 199
Pharmacotherapy of type 2 diabetes: An update and future directions
DeMarsilis, A. J., Reddy, N., Boutari, C., Filippaios, A., Sternthal, E., Katsiki, N., & Mantzoros, C. S. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155332 · Cited by 184
Interventions for Reversing Prediabetes: A Systematic Review and Meta-Analysis
Galaviz, K. I., Weber, M. B., Suvada, K., Gujral, U. P., Wei, J., Merchant, R., Dharanendra, S., Haw, J. S., Narayan, K. M. V., & Ali, M. K. (2022) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2021.10.020 · Cited by 149
Retnakaran, R., Kramer, C. K., Choi, H., Swaminathan, B., & Zinman, B. (2014) · Diabetes Care · doi:10.2337/dc14-0893 · Cited by 136
Clinical Considerations for Use of Initial Combination Therapy in Type 2 Diabetes
Cahn, A., & Cefalu, W. T. (2016) · Diabetes Care · doi:10.2337/dcs15-3007 · Cited by 118
“Furthermore, improvement in b-cell function has been demonstrated to be the predominant underlying pathophysiological mechanism in inducing glycemic remission from impaired glucose tolerance to normal glucose tolerance with pioglitazone in the Actos Now for the prevention of diabetes (ACT NOW) study, further underpinn…”
BackgroundWhen β‐cells fail: lessons from dedifferentiation
Accili, D., Talchai, S. C., Kim-Muller, J. Y., Cinti, F., Ishida, E., Ordelheide, A., Kuo, T., Fan, J., & Son, J. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12723 · Cited by 117
“Thus, an overarching Foxo1-dependent mechanism regulating β-cell function can explain the interaction of insulin resistance with hyperglycaemia as causes of β-cell failure, and offers a potential explanation for the benefits of glucose-lowering agents as well as insulin sensitizers on β-cell function.(62)”
BackgroundKim-Muller, J. Y., Zhao, S., Srivastava, S., Mugabo, Y., Noh, H.-L., Kim, Y. R., Madiraju, S. R. M., Ferrante, A. W., Skolnik, E. Y., Prentki, M., et al. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.08.012 · Cited by 100
“, that they shunt lipids from oxidation to synthesis, preventing lipid-fueled toxicity (Defronzo et al., 2013; Leahy, 2009).”
Pharmacological approaches to the prevention of type 2 diabetes mellitus
Majety, P., Orquera, F. A. L., Edem, D., & Hamdy, O. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1118848 · Cited by 149
PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients
Lange, N. F., Graf, V., Caussy, C., & Dufour, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084305 · Cited by 96
Insulin Resistance the Link between T2DM and CVD: Basic Mechanisms and Clinical Implications
Abdul‐Ghani, M. A., Jayyousi, A., DeFronzo, R. A., Asaad, N., & Suwaidi, J. M. S. A. (2017) · Current Vascular Pharmacology · doi:10.2174/1570161115666171010115119 · Cited by 81
Self-citationThe RISE Consortium, Ehrmann, D. A., Temple, K. A., Rue, A., Barengolts, E., Mokhlesi, B., Van Cauter, E., Sam, S., Miller, M. A., Kahn, S. E., et al. (2019) · Diabetes Care · doi:10.2337/dc19-0556 · Cited by 73
Self-citationPunicic acid: A potential compound of pomegranate seed oil in Type 2 diabetes mellitus management
Khajebishak, Y., Payahoo, L., Alivand, M. R., & Alipour, B. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27556 · Cited by 81
“…tissues), ameliorating dyslipidemia, and decreasing inflammatory cytokines (e.g., TNF‐α and interleukin 6; American Diabetes Association, 2005; DeFronzo et al., 2013; Rizos, Liberopoulos, Mikhailidis, & Elisaf, 2008; Stumvoll et al., 2005; Xiang et al., 2006), some side effects of TZDs…”
BackgroundDefinition of intervention points in prediabetes
Ferrannini, E. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70175-x · Cited by 72
Armato, J., DeFronzo, R. A., Abdul-Ghani, M. A., & Ruby, R. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30234-1 · Cited by 70
Self-citationCardiovascular impact of drugs used in the treatment of diabetes
Triggle, C. R., & Ding, H. (2014) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622314546125 · Cited by 67
Bashier, A. M., Hussain, A. K. B., Abdelgadir, E., Alawadi, F., Sabbour, H. M., & CHILTON, R. J. (2019) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-019-0476-0 · Cited by 67
Emerging Treatment Strategies for Diabetes Mellitus and Associated Complications: An Update
Mishra, V. K., Nayak, P., Sharma, M., Albutti, A., Alwashmi, A. S. S., Aljasir, M. A., Alsowayeh, N., & Tambuwala, M. M. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13101568 · Cited by 77
“These are utilized as a treatment protocol for insulin-resistant patients with T2DM [15].”
MethodInfluentialPrediabetes Deserves More Attention: A Review
Lawal, Y., Bello, F., & Kaoje, Y. S. (2020) · Clinical Diabetes · doi:10.2337/cd19-0101 · Cited by 61
Unnikrishnan, R., Shaw, J. E., Chan, J. C. N., Wild, S. H., Peters, A. L., Orrange, S., Roden, M., & Mohan, V. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00635-0 · Cited by 76
“The Actos Now for the prevention of diabetes (ACT NOW) trial 137,165 found that pioglitazone was associated with lower diabetes incidence and higher conversion to normal glucose tolerance than placebo (Table 3).”
Kramer, C. K., Zinman, B., Choi, H., & Retnakaran, R. (2016) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2016-000270 · Cited by 58
Abdul-Ghani, M., Puckett, C., Adams, J., Khattab, A., Baskoy, G., Cersosimo, E., Triplitt, C., & DeFronzo, R. A. (2021) · Diabetes Care · doi:10.2337/dc20-0978 · Cited by 55
“After screening, eligible participants underwent 1) a 75-g oral glucose tolerance test (OGTT) and 2) ultrasound measurement of carotid intima-media thickness (CIMT) (15).”
BackgroundMethodInfluentialSelf-citationDeFronzo, R. A., CHILTON, R. J., Norton, L., Clarke, G., Ryder, R. E. J., & Abdul‐Ghani, M. A. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12652 · Cited by 55
“Pioglitazone also exerts a powerful effect to improve β-cell function [36,40] which, combined with its potent insulin-sensitizing action, explains its durable effect in reducing HbA1c levels [28,41].”
BackgroundSelf-citationEffect of pioglitazone on plasma ceramides in adults with metabolic syndrome
Warshauer, J. T., Lopez, X., Gordillo, R., Hicks, J., Holland, W. L., Anuwe, E., Blankfard, M. B., Scherer, P. E., & Lingvay, I. (2015) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2662 · Cited by 51
“This is further supported by the ACT NOW Study, which showed improved insulin sensitivity in patients with impaired glucose tolerance treated with pioglitazone [30].”
ResultTripathy, D., Schwenke, D. C., Banerji, M., Bray, G. A., Buchanan, T. A., Clement, S. C., Henry, R. R., Kitabchi, A. E., Mudaliar, S., Ratner, R. E., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-4202 · Cited by 48
Self-citationSemnani-Azad, Z., Connelly, P. W., Bazinet, R. P., Retnakaran, R., Jenkins, D. J. A., Harris, S. B., Zinman, B., & Hanley, A. J. (2021) · Diabetes Care · doi:10.2337/dc20-1918 · Cited by 41
The metabolic vascular syndrome - guide to an individualized treatment
Hanefeld, M., Pistrosch, F., Bornstein, S. R., & Birkenfeld, A. L. (2016) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-016-9345-4 · Cited by 50
Wilson, M. L. (2017) · Nursing Clinics of North America · doi:10.1016/j.cnur.2017.07.011 · Cited by 50
The Disposition Index Does Not Reflect β-Cell Function in IGT Subjects Treated With Pioglitazone
DeFronzo, R. A., Tripathy, D., Abdul-Ghani, M., Musi, N., & Gastaldelli, A. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1515 · Cited by 34
Self-citationPrevention of type 2 Diabetes Mellitus: Potential of pharmacological agents
Samson, S. L., & Garber, A. J. (2016) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2016.06.005 · Cited by 37
“insulin sensitivity and insulin secretion, consiste nt with the TRIPOD findings[36].”
MethodMitochondrial target of thiazolidinediones
Colca, J. R., McDonald, W. G., & Kletzien, R. F. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12308 · Cited by 34
Therapeutic Approaches for Preserving or Restoring Pancreatic β-Cell Function and Mass
Jung, K. Y., Kim, K. M., & Lim, S. K. (2014) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2014.38.6.426 · Cited by 34
“In the Actos Now for Prevention of Diabetes (ACT NOW) study, pioglitazone decreased the rate of conversion of subjects from having impaired glucose tolerance (IGT) to T2DM by 72% and significantly improved insulin sensitivity and β-cell function [30].”
Abdul-Ghani, M. A., Jobori, H. A., Daniele, G., Adams, J. M., Cersósimo, E., Triplitt, C. L., & DeFronzo, R. A. (2017) · Diabetes · doi:10.2337/db17-0055 · Cited by 33
“Thus, unlike the current study in which the increase in EGP in subjects with NFG closely matches the urinary glucose loss, the increase in urinary glucose excretion in subjects with T2DM exceeded the increase in EGP, and the FPG concentration declined.”
BackgroundInfluentialSelf-citationChanging the Concept of Type 2 Diabetes: Beta Cell Workload Hypothesis Revisited
Saisho, Y. (2018) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530318666180821161825 · Cited by 30
New Aspects of Diabetes Research and Therapeutic Development
Satin, L. S., Soleimanpour, S. A., & Walker, E. M. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000160 · Cited by 34
What are the pharmacotherapy options for treating prediabetes?
Daniele, G., Abdul‐Ghani, M. A., & DeFronzo, R. A. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.944160 · Cited by 26
“Although TZDs markedly improve insulin sensitivity in IGT individuals, enhanced b-cell function is the strongest predictor of T2DM prevention [110].”
BackgroundSelf-citationIpsen, E. Ø., Madsen, K. S., Chi, Y., Pedersen-Bjergaard, U., Richter, B., Metzendorf, M.-I., & Hemmingsen, B. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013516.pub2 · Cited by 23
Schwartz, S. S., Jellinger, P. S., & Herman, M. E. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2016.1191955 · Cited by 24
The Natural Course of Impaired Fasting Glucose
Święcicka-Klama, A., Połtyn–Zaradna, K., Szuba, A., & Zatońska, K. (2020) · Advances in experimental medicine and biology · doi:10.1007/5584_2020_571 · Cited by 23
the ACT NOW Study Investigators, Hu, X., Reaven, P. D., Saremi, A., Liu, N., Abbasi, M. A., Liu, H., & Migrino, R. Q. (2016) · EURASIP Journal on Bioinformatics and Systems Biology · doi:10.1186/s13637-016-0049-6 · Cited by 23
Self-citationJagannathan, R., Snehalatha, C., Selvam, S., Nanditha, A., Shetty, A. S., Godsland, I. F., Johnston, D. G., & Ramachandran, A. (2015) · Acta Diabetologica · doi:10.1007/s00592-015-0718-z · Cited by 20
Kramer, C. K., Zinman, B., Choi, H., & Retnakaran, R. R. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1947 · Cited by 18
“gluc0–120 Matsuda index (where ISR is the prehepatic insulin secretion rate determined by C-peptide deconvolution), as previously described (10, 19, 20).”
MethodKim, J. M., Kim, S. S., Kim, J. H., Kim, M.-K., Kim, T. N., Lee, S. H., Lee, C. W., Park, J. Y., Kim, E. S., Lee, K. J., et al. (2019) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2018.0274 · Cited by 17
Bedogni, G., Gastaldelli, A., Tiribelli, C., Agosti, F., Col, A. D., Fessehatsion, R., & Sartório, A. (2014) · Journal of Endocrinological Investigation · doi:10.1007/s40618-014-0101-x · Cited by 15
“Subjects and methods We studied 61 Caucasian women aged 18–60 years without T2DM and with a body mass index ranging from 35.3 to 48.8 kg/m2.”
InfluentialSelf-citationHan, F., Li, X., Yang, J., Liu, H., Zhang, Y., Yang, X., Yang, S., Chang, B., Chen, L., & Chang, B. (2019) · Aging and Disease · doi:10.14336/ad.2018.1221 · Cited by 15
“cell function in this setting is destined for rapid, steady decline [33, 34].”
BackgroundTharp, W. G., Gupta, D., Sideleva, O., Deacon, C. F., Holst, J. J., Elahi, D., & Pratley, R. E. (2019) · Diabetes · doi:10.2337/db18-1163 · Cited by 16
“Clinical trials of TZDs demonstrate improved glucose and lipid control, enhanced peripheral Si, and preservation of b-cell function in prediabetes and early T2DM compared with other therapies (42,43).”
ResultJetton, T. L., Flores-Bringas, P., Leahy, J. L., & Gupta, D. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101250 · Cited by 16
Treat Obesity to Treat Type 2 Diabetes Mellitus
Sulu, C., & Yumuk, V. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01536-3 · Cited by 24
Moon, J. H., Choe, H. J., & Lim, S. K. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14221 · Cited by 15
“These changes correlate with insulin secretion response, insulin sensitivity, and b -cell function 133 .”
BackgroundGiuseppe, G. D., Ciccarelli, G., CEFALO, C. M. A., Cinti, F., Moffa, S., Impronta, F., Capece, U., Pontecorvi, A., Giaccari, A., & Mezza, T. (2021) · Minerva Endocrinology · doi:10.23736/s2724-6507.21.03405-9 · Cited by 17
An overview of alogliptin + pioglitazone for the treatment of type 2 diabetes
Tomlinson, B., Chan, P., & Lam, C. W. K. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1985465 · Cited by 19
Espinoza, S. E., Wang, C.-P., Tripathy, D., Clement, S. C., Schwenke, D. C., Banerji, M. A., Bray, G. A., Buchanan, T. A., Henry, R. R., Kitabchi, A. E., et al. (2016) · AGE · doi:10.1007/s11357-016-9946-6 · Cited by 14
“Pioglitazone is thought to improve β cell function and ameliorate insulin resistance through its action on the peroxisome proliferator-activated receptor (PPAR)-γ (DeFronzo et al. 2013).”
BackgroundMethodSelf-citationPathogenesis of Type 2 Diabetes Mellitus
DeFronzo, R. A. (2018) · Endocrinology · doi:10.1007/978-3-319-45015-5_8 · Cited by 16
Self-citationChianelli, M., Armellini, M., Carpentieri, M. S., Coccaro, C., Cuttica, C. M., Fusco, A., Marucci, S., Nelva, A., Nizzoli, M., Ponziani, M. C., et al. (2024) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/0118715303282327240507184902 · Cited by 15
Hsiao, P.-J., Wu, K.-L., Chiu, S.-H., Chan, J., Lin, Y., Wu, C., Wu, C., Kao, S., Fang, T., Lin, S., et al. (2016) · Clinical and Experimental Nephrology · doi:10.1007/s10157-016-1330-4 · Cited by 12
Zhang, X., Cui, X., Jin, X., Han, F., Wang, J., Yang, X., Xu, J., Shan, C., Gao, Z., Li, X., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00300 · Cited by 14
Prevention of type 2 diabetes: what is the right target population?
Williamson, D. A. (2018) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2018.1535896 · Cited by 13
“Metformin and other medications [20,21,24,26,27] also have been found to be effective for preventing T2D and for improving β cell function [23].”
BackgroundPathogenesis of Type 2 Diabetes Mellitus
DeFronzo, R. A. (2018) · Endocrinology · doi:10.1007/978-3-319-27317-4_8-1 · Cited by 13
Self-citationRehabilitation of pioglitazone
Ryder, R. E. J., & DeFronzo, R. A. (2015) · The British Journal of Diabetes · doi:10.15277/bjdvd.2015.021 · Cited by 11
Self-citationThe color of fat and its central role in the development and progression of metabolic diseases
Gaggini, M., Carli, F., & Gastaldelli, A. (2017) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2017-0060 · Cited by 12
Self-citationCollier, J. J., Batdorf, H. M., Merrifield, K. L., Martin, T. M., White, U. A., Ravussin, É., Burk, D. H., Cooley, C. R., Karlstad, M. D., & Burke, S. J. (2021) · Biomedicines · doi:10.3390/biomedicines9091189 · Cited by 12
“We observed that oral delivery of the TZD pioglitazone (PIO), an insulin-sensitizer prescribed to patients with prediabetes or existing T2D [11,27,28], counteracted these pathological metabolic outcomes.”
BackgroundAberer, F., Pieber, T. R., Eckstein, M. L., Sourij, H., & Moser, O. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061180 · Cited by 12
“TZDs might have beneficial effects in preserving β-cell function in T2D, as suggested by the use of rosiglitazone (DREAM trial) and pioglitazone (ACT NOW trial), and thus slowing down the progression of prediabetes into diabetes [97,98].”
BackgroundAbdul‐Ghani, M. A., Migahid, O., Megahed, A., Singh, R., Kamal, D., DeFronzo, R. A., & Jayyousi, A. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13189 · Cited by 9
Self-citationMetabolic effects and mechanism of action of the pan-PPAR agonist lanifibranor
Sabatini, S., & Gastaldelli, A. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.03.003 · Cited by 11
Self-citationSchwartz, S. S., Corkey, B. E., Gavin, J. R., DeFronzo, R. A., & Herman, M. E. (2024) · BMC Medicine · doi:10.1186/s12916-024-03518-5 · Cited by 12
“The ACT-NOW and STOP-Diabetes trials showed that correcting impaired insulin secretion and insulin resistance in nor-moglycemic people at high risk of diabetes (impaired glucose tolerance or prediabetes in these two studies, respectively) reduced progression to frank diabetes [74, 75].”
BackgroundSelf-citationThe Metabolic Syndrome and Cardiovascular Diseases: An Update of Medical Treatment
Pistrosch, F. (2014) · Journal of Metabolic Syndrome · doi:10.4172/2167-0943.1000160 · Cited by 6
“Evidence with antidiabetic drugs for the prevention of type 2 diabetes in people with abnormal glucose tolerance is available only for metformin [55], acarbose [56] and thiazolidinediones [57-59].”
BackgroundKim, Y. K., Hwang, J. G., & Park, M. K. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s302215 · Cited by 8
ALi, A., Manzoor, U., Ali, S. L., Marsool, M. D. M., Parida, P. K., Marsool, A. D. M., & Swathi, N. L. (2023) · doi:10.53555/jptcp.v30i18.3467 · Cited by 7
Real-world diabetes prevention: from theory to practice
Ryder, R. E. J. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30267-5 · Cited by 6
How Does Pioglitazone Prevent Progression of Impaired Glucose Tolerance to Diabetes?
GENUTH, S. M. (2013) · Diabetes · doi:10.2337/db13-1175 · Cited by 7
Asgari, P., Esmaeili, N., Khorami, N. S., & Bakhtiarpour, S. (2021) · International Archives of Health Sciences · doi:10.4103/iahs.iahs_115_20 · Cited by 6
Unveiling Diabetes: Categories, Genetics, Diagnostics, Treatments, and Future Horizons
Alam, A., Dhoundiyal, S., Ahmad, N., & Rao, G. K. (2023) · Current Diabetes Reviews · doi:10.2174/1573399820666230818092958 · Cited by 7
Integration of systems biology with organs-on-chips to humanize therapeutic development
Edington, C., Cirit, M., Chen, W. L. K., Clark, A. M., Wells, A. H., Trumper, D. L., & Griffith, L. G. (2017) · Proceedings of SPIE, the International Society for Optical Engineering/Proceedings of SPIE · doi:10.1117/12.2256078 · Cited by 5
RECENT ADVANCES IN TREATMENT APPROACHES FOR DIABETES MELLITUS AND RELATED COMPLICATIONS: A REVIEW
Dhyani, S., Butola, M., Sautha, V., & Jakhmola, V. (2025) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2025v17i2.53184 · Cited by 11
Masulli, M., Pepa, G. D., Cocozza, S., Capasso, M., Pignataro, P., Vitale, M., Gastaldelli, A., Russo, M., Dolce, P., Riccardi, G., et al. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3392 · Cited by 4
Self-citationDoi, S. A. R., & Ward, G. M. (2014) · Endocrine · doi:10.1007/s12020-014-0284-0 · Cited by 3
Kunyiha, N., Adan, R., Ngugi, R., Odhiambo, J., & Sokwalla, S. (2025) · Current Diabetes Reports · doi:10.1007/s11892-025-01581-7 · Cited by 3
D’Alessio, D. A., & Kahn, S. E. (2025) · Diabetes · doi:10.2337/dbi24-0049 · Cited by 2
Alogloptin and pioglitazone. Perspectives of combined administration
Demidova, T. Y., & Kochina, A. S. (2021) · Endocrinology News Opinions Training · doi:10.33029/2304-9529-2021-10-4-62-68 · Cited by 2
Ruyatkina, L. A., Ruyatkin, D. S., & Iskhakova, I. S. (2021) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2021-7-33-44 · Cited by 2
LncRNA ‐ Snhg3 regulates mouse hepatic glycogenesis under normal chow diet
Xie, X., Gao, M., Wang, H., Zhang, M., Zhao, W., Li, C., Zhang, W., Yang, J., Zhang, Y., Chen, E., et al. (2024) · The FASEB Journal · doi:10.1096/fj.202401064r · Cited by 2
Gc inhibition preserves insulin sensitivity and reduces body weight without loss of muscle mass
Gill, R., & Kuo, T. (2025) · JCI Insight · doi:10.1172/jci.insight.195341 · Cited by 2
Gastaldelli, A., Choi, E., Conde‐Knape, K., Göransson, O., Krook, A., Lehtonen, S. H., Roden, M., Schrauwen, P., Sparks, L. M., & Heni, M. (2026) · Diabetologia · doi:10.1007/s00125-026-06853-9 · Cited by 3
Self-citationThe Metabolic Syndrome and Cardiovascular Diseases: An Update of Medical
Pistrosch, F., Schulze, J., & Rothe, U. (2014) · Cited by 1
Evaluating the Evidence behind the Novel Strategy of Early Combination from Vision to Implementation
Paldánius, P. M. (2020) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0179 · Cited by 2
Special Issue: Emerging Paradigms in Insulin Resistance
Collier, J. J., & Burke, S. J. (2022) · Biomedicines · doi:10.3390/biomedicines10071471 · Cited by 1
Ansquer, J.-C. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-26681-2_6 · Cited by 4
Li, Y.-Q., Zhang, L., Zhao, Y., Xu, F., Hu, Z., Wu, Q.-H., Li, W., & Li, Y.-N. (2023) · World Journal of Diabetes · doi:10.4239/wjd.v14.i11.1643 · Cited by 1
Metabolic health and strategies for a Healthier SG
Khoo, J. J. C., Lim, R. L. C., Ng, L. P., Phoon, I. K. Y., Gani, L. U., Puar, T. H. K., How, C. H., & Loh, W. J. (2025) · Singapore Medical Journal · doi:10.4103/singaporemedj.smj-2025-157 · Cited by 1
“[62] In SHP, metformin may be initiated for patients with prediabetes and HbA1c persistently above 6.0% despite 6 months of lifestyle intervention.”
InfluentialNewer therapeutic approaches towards the management of diabetes mellitus: an update
Lin, H.-L., SHUKRI, F. N. M., YIH, E. S., SHA, G. H., JING, G. S., Jin, G. W., HOONG, C. W., YING, C. Q., Panda, B. P., Candasamy, M., et al. (2021) · Panminerva Medica · doi:10.23736/s0031-0808.19.03655-3 · Cited by 1
Systemic benefits of Gc inhibition to preserve insulin sensitivityPreprint
Kuo, T., & Accili, D. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.10.06.328963 · Cited by 1
“TZDs, whose use has fallen out of fashion due to a combination of adverse side effects and regulatory setbacks (39), remain the only class of drugs consistently associated with an effect on diabetes prevention (9-11).”
BackgroundSadeghi, A., Ali, S., Asl, S., & Helan, J. (2013)
Glucotoxicité et lipotoxicité dans le diabète de type 2 : comment protéger la cellule β ?
Scheen, A. J. (2020) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2020.05.005
Metadata
- Authors
- DeFronzo, R. A., Tripathy, D., Schwenke, D. C., Banerji, M., Bray, G. A., Buchanan, T. A., Clement, S. C., Gastaldelli, A., Henry, R. R., Kitabchi, A. E., Mudaliar, S., Ratner, R. E., Stentz, F. B., Musi, N., Reaven, P. D., & Study, F. T. A. N.
- Affiliations
- The University of Texas at San Antonio Health Science Center (US)
- Phoenix VA Health Care System (US)
- SUNY Downstate Health Sciences University (US)
- Pennington Biomedical Research Center (US)
- University of Southern California (US)
- Georgetown University (US)
- University of California San Diego (US)
- University of Tennessee Health Science Center (US)
- MedStar Health Research Institute (US)
- Corresponding author
- DeFronzo, Ralph A.
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2013-10-18
- Volume
- 62
- Issue
- 11
- Pages
- 3920-3926
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC3806596
- OpenAlex
- W2103930636
- Cited by
- 109
- References
- 42
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 5 · 2023: 5 · 2022: 7 · 2021: 12 · 2020: 11 · 2019: 6 · 2018: 8 · 2017: 8 · 2016: 11 · 2015: 7 · 2014: 14 · 2013: 2
- FWCI
- 8.91
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- AstraZeneca
- Sanofi
- Gilead Sciences
- University of Southern California
- Intarcia Therapeutics
- Novo Nordisk
- National Institutes of Health (UL1TR000130)
- Health Science Center, University of Tennessee
- Allergan
- National Center for Research Resources (M01-RR00221)
- National Center for Advancing Translational Sciences
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- pioglitazone, type 2 diabetes prevention, impaired glucose tolerance, insulin sensitivity, Matsuda index, insulin secretion, insulin resistance, beta-cell function, glucose tolerance, thiazolidinediones
- MeSH terms
- Pioglitazone, Blood Glucose, Diabetes Mellitus, Type 2, Female, Glucose Tolerance Test, Humans, Insulin, Insulin Resistance, Male, Middle Aged, Glucose Intolerance, Thiazolidinediones, Insulin-Secreting Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.